FSD Pharma Brief: Signed Agreement With INGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Brief: Signed Agreement With INGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma 簡介：與 inGenu CRO 簽署協議，進行一項臨床研究，以評估健康成人體內多個遞增劑量 Lucid-21-302 (Lucid-MS) 的安全性和藥代動力學
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊